Description
MaxCyte, Inc. is a life sciences company. The Company is focused on advancing the discovery, development and commercialization of cell therapies.
The Company provide cell-engineering platform to biopharmaceutical partners engaged in drug discovery and development, biomanufacturing and cell therapy, including gene editing and immuno-oncology.
MaxCyte has developed and commercialized Flow Electroporation platform, which facilitates engineering of a wide variety of cells. The Company's ExPERT platform, which is based on Flow Electroporation technology, is designed to address the expanding cell therapy market, and used across the continuum of the cell therapy sector. The ExPERT family of products includes: three instruments, the ATx, STx and GTx. MaxCyte has also developed CARMA, a therapeutic platform based on transfecting mRNA into unstimulated cells for the development of immune cell therapies.
